Skip to main content
PMC home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Jul 13.
Published in final edited form as: Niger Postgrad Med J. 2019 Apr-Jun;26(2):80–86. doi: 10.4103/npmj.npmj_59_19

Pattern of Prevalent Hepatitis B Virus Genotypes in Zaria, Nigeria

Abdurrahman Elfulaty Ahmad 1, Adamu Girei Bakari 1, Bolanle Olufunke Priscilla Musa 1, Shettima Kagu Mustapha 1, Bello Yusuf Jamoh 1, Idris Nasir Abdullahi 2, Mohammed Ibrahim Tahir 2, Abdulqadri Olarenwaju Olatunji 3, Sumayya Hamza Maishanu 3, Ahmed Babangida Suleiman 4, Afolaranmi Tolulope 5, Claudia Hawkins 6, Atiene Solomon Sagay 7, Ayuba Zoakah 5, Adebola Tolulope Olayinka 8
PMCID: PMC6626198  NIHMSID: NIHMS1035126  PMID: 31187746

Abstract

Background:

Hepatitis B virus (HBV) is hyperendemic in Nigeria. Available literature reveal genotype E as being predominant in West Africa. This study aimed at identifying the current pattern and prevalent genotypes of HBV in Zaria, Nigeria.

Materials and Methods:

Four millilitre of blood was collected in ethylenediaminetetraacetic acid-container from each of 165 HBV surface antigen-positive participants recruited purposively from the gastroenterology clinic from May to August, 2017. Plasma was separated and frozen at −20°C till analysis. Multiplex-nested polymerase chain reaction using type-specific primers was used to identify the various HBV genotypes.

Results:

Median (and interquartile range ) age of the participants was 31.0 (25.5–39.0) years, with males constituting 107 (64.8%). Majority (83.6%) of the samples analysed were HBV-DNA-positive with 82.6% of the HBV-DNA-positive samples being mixed genotype infections. Irrespective of mode of occurrence, five HBV genotypes were identified with HBV/E (97.1%) being the most predominant, followed by HBV/B (82.6%), HBV/A (24.6%), then HBV/C (17.4%), while HBV/D (0.7%) was the least prevalent.

Conclusion:

In most (99.1%) of the mixed-infection were a combination of genotype E, the predominant genotype, with other genotypes predominantly genotype B. HBV genotypes E, B, A, C and D are the prevalent genotypes in Zaria, Nigeria, as they occur in single genotype and in mixed-genotypes pattern.

Keywords: Genotypes, hepatitis B Virus, mixed-infection, Nigeria, Zaria

Introduction

Hepatitis B virus (HBV) is one of the major causes of morbidity and mortality worldwide.[1] About 2 billion people are thought to have evidence of the past or present infection with HBV, with about 240 million chronic carriers of HBV surface antigen (HBsAg).[2] Worldwide, approximately 650,000 people die each year from complications of chronic hepatitis B.[3] In Nigeria, HBV infection is hyperendemic with the seroprevalence of HBsAg ranging from 10% to 40%.[4–8]

Recently, ten genotypes of HBV (A through J) have been identified on the basis of 8% or less difference in genome sequences, each with a distinctive geographical distribution.[9,10] In Sub-Saharan Africa, genotypes E is predominant in the region, followed by genotypes A and D.[11,12] Different HBV genotypes present different clinical outcome and response to interferon-based therapy. Typically, infections with HBV genotypes A and D tend to progress to chronic phase than genotypes B and C, while genotypes A and B have higher rates of spontaneous HBeAg seroconversion compared to C and D.[13] Genotype E, the most common HBV genotype in the West African region is associated with poor response to interferon-based therapy and is also moderately associated with pre-core and basal-core promoter mutations.[14,15] Moreover, recent studies elsewhere show unusual HBV mixed genotype infections, suggesting overlapping clinical outcomes.[16] In this study area, there is no prior study identifying the prevalent HBV genotypes and their pattern of infection. Therefore, this study aimed at identifying the current pattern and prevalent genotypes of HBV in Zaria, Nigeria.

Materials and Methods

Ethics statement

Ethical approval (dated: 25th January, 2017; Reference Number: ABUTH/HREC/Y5/2016) was obtained from the Health Research Ethics Committee of Ahmadu Bello University Teaching Hospital, Zaria, before the commencement of sample collection. Written informed consent was sought and obtained from each participant prior to enrolment into the study as all the participants were adults. The participants were adequately informed of their right to choose to or not participate or withdraw at any point they so wished. All data were treated with the utmost confidentiality.

Minimum sample size determination

The minimum sample size was calculated using single proportion formula:

N=Z2Pq/d2

where

N = Minimum sample size

Z2 = Standard Normal deviate set at 1.96.

P = Prevalence rate of 12.2% (0.122) was recorded according to Olayinka et al.[8]

d = acceptable error of 5% (0.05)

Therefore, the minimum sample size was calculated to be 165.

Study area and subjects

This study was conducted in the gastroenterology clinic from May to August 2017. Zaria is a major city in Kaduna State of Northern Nigeria housing multiple Federal Government parastatals in addition to the study centre, such as the Ahmadu Bello University, the Nigerian College of Aviation Technology, the Nigerian Institute for Chemical and Leather Technology and Nigerian Institute for Transport Technology, among others. One hundred and sixty-five study participants with known chronic HBV infection were recruited purposively and had 4 mL of their venous blood samples collected. Chronic phase was defined by minimum of 6 months of infection obtained from their clinical records in the gastroenterology clinic.

Sample collection and storage

For the analysis, the collected ethylenediaminetetraacetic acid-anticoagulated blood was centrifuged at 2800 × xg for 5 min to separate the plasma. All samples collected were first tested immunochromatographically for HCV and HIV for exclusion, then reconfirmed for HBsAg status using FaStep rapid immunochromatographic test strip (Polymed Therapeutics, Inc. Houston, USA). The separated plasma was then transferred into cryovials and stored at −20°C till analysis. All the plasma were separated in Immunology Laboratory of the Teaching Hospital and transported in cold chain to DNA LABS Kaduna, Nigeria, where Hepatitis B viral genotyping was conducted.

Hepatitis B virus DNA detection and genotyping by nested polymerase chain reaction

Multiplex-nested polymerase chain reaction (PCR) using type-specific primers [Table 1] was used to assign genotypes A through F based on pre-S1 through S genes of the HBV genome. The design of the HBV genotype-specific primers is based on the conserved regions of the sequences in a particular genotype and discordance in homology with the sequences of other HBV genotypes.[17] Five such different sets of primers were used: P1 and S1–2 being the universal outer primers and B2 was used as the inner sense (forward) primer with a combination of BA1R, BB1R and BC1R as anti-sense (reverse) inner primers for genotypes A, B and C, respectively, in a multiplex system tagged ‘Mixture A’. For genotypes D, E and F, an anti-sense primer B2R was used in combination with BD1, BE1and BF1 as sense (forward) primers, also in a multiplex system tagged ‘Mixture B’. List and classification of primers used are shown in Table 1.

Table 1:

Sequences of primers for hepatitis B virus amplification and genotyping used by multiplex-nested polymerase chain reaction

Primer Sequence (5’–3’) Specificity Position Polarity
1st round PCR
 PI TCACCATATTCTTGGGAACAAGA Universal 2823–2845 Sense
 Sl-2 CGAACCACTGAACAAATGGC Universal 685–704 Antisense
2nd round PCR: Mix A
 B2 GGCTCCAGTTCCGGAACAGT Type A-E 67–86 Sense
 BA1R CTCGCGGAGATTGACGAGATGT Type A 113–134 Antisense
 BB1R GGTCCTAGGAATCCTGATGTTG TypeB 165–186 Antisense
 BC1R CAGGTTGGTGAGCTGGAGA TypeC 2979–2996 Antisense
2nd round PCR: Mix B
 B2R GGAGGCGGATTTGCTGGCAA Type D-F 3078–3097 Antisense
 BD1 GCCAACAAGGTAGGAGCT Type D 2979–2996 Sense
 BE1 CACCAGAAATCCAGATTGGGACCA Type E 2955–2978 Sense
 BF1 GTTACGGTCCAGGGTTACCA Type F 3032–3051 Sense
Open in a new tab

Hepatitis B virus DNA extraction

HBV DNA was extracted from plasma of HBsAg-positive participants using the Bioneer AccuPrep Genomic DNA extraction kit according to the manufacturer’s instructions.

First-round polymerase chain reaction: Hepatitis B virus DNA detection

The final reaction volume for the first round of the nested PCR was 20 μL. The premix tubes were labelled with the sample ID. Two microlitres of extracted DNA was added to a Master Mix (cocktail of 16 μL of deionised water [D.H2O] and premix of 250 μM of each dNTP, 1X PCR buffer, 15 mM of MgCl2 and 1U of thermostable Taq polymerase) and 1 μL each of P1 (forward) and S1–2 (reverse) outer primers. The PCR was performed using thermal cycler (PTC-100™ Programmable thermal controller, MJ Research, Inc.) and reaction conditions were set as: initial activation at 95°C for 5 min; denaturation at 94°C for 20 s; annealing at 55°C for 20 s and extension at 72°C for 1 min. Complete sets of 30 cycles from denaturation to extension were observed. Then, the final extension was set at 72°C for 5 min.

Second-round polymerase chain reaction: Hepatitis B virus genotyping

Second-round PCR was performed in two different tubes for each sample, one with the common universal sense primer (B2) and type-specific primers for genotypes A, B, C in ‘Mixture A’ and the other with the common universal anti-sense primer B2R and type-specific primers for genotypes D, E, F in ‘Mix-B’. Seventeen microliters of D.H2O was added into each tube of premix ‘A’ and ‘B’. Two microlitres of the cocktail of primers (containing 0.5 μL each of the four primers) were added into the mixtures. One microliter of the first-round PCR product into each tube of the premix. The mixture was mixed gently and centrifuged. The PCR condition was set as: initial activation at 94°C for 3 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 50°C for 1 min and extension at 72°C for 1 min for both ‘Mix A’ and ‘Mix B’, with the final extension at 72°C for 5 min. Primers used were adopted from previous studies.[18, 19] Twenty microliters of each of negative control, samples and the ladder were run on 2% agarose gel (2% w/v in 1 × TAE buffer) and electrophoresed in 1 × TAE buffer for 45 min at 100V. The bands were visualised under gel documentation system (BioRad Gel Doc-XR, USA) and screenshots captured. The size of the separated bands (DNA fragments) was compared with the GeneRuler™ 100 bp + DNA ladder (MBI Fermentas, Life Sciences, Canada). We deposited the detailed procedure we used for the HBV genotyping on protocols.io.[20]

Statistical analysis

The data were collated and validated using Epi Info ® questionnaire database (CDC, Atlanta, Georgia, USA). It was then analysed using GraphPad Prism 6 statistical software package (GraphPad Software, Inc. San Diego, California, USA). Frequencies and percentages of the identified genotypes were presented in tables and charts, while age was presented as median (and interquartile range  [IQR]). Chi-squared test with Yates correction was used to determine the relationship between identified HBV genotypes and sex and age groups.

Results

Sociodemographic characteristics

The median (and IQR) age of the 165 HBsAg-positive participants was 31.0 (25.5–39.0) years. Male participants constituted 64.8% (107/165) of the total number recruited. Age group of 18–27 years constituted the highest number of participants with 62 (37.6%), which was followed by the 28–37 year group with 55 (33.3%), then the 38–47 and 48–57-year groups with 33 (20.0%) and 15 (9.1%), respectively. Those with tertiary education constituted the majority of the participants with 80 (48.5%) and were followed by those in the secondary level with 46 (27.6%), those with only Qur’anic/Islamic education with 17 (10.3%), those in post-graduate level with 12 (7.3%), then those with only primary education with 9 (5.5%) and only 1 (0.6%) individual without any form of education. Civil servants were the highest number of participants with 49 (29.7%), followed by the self-employed, students, homemakers, others, non-governmental employees and retirees with 40 (24.2%), 38 (23.0%), 30 (18.2%), 4 (2.4%), 3 (1.8%) and 1 (0.6%), respectively. Ninety-nine (60%) of the study participants were married men and women, and this was followed by singles with a frequency of 59 (35.8%). Widowed women and divorced participants had a frequency of 4 (2.4%) and 3 (1.8%), respectively. All these characteristics and distributions are as shown in Table 2.

Table 2:

Sociodemographic characteristics of hepatitis B virus surface antigen-positive study participants in Zaria, Nigeria (n=165)

Variable Frequency (%) 95% Cl
Median age (IQR), years 31.0 (25.5–39.0)
Gender
 Male 107 64.8 (57.0–72.1)
 Female 58 35.2 (27.9–43.0)
Age group (years)
 18–27 62 37.6 (30.2–45.4)
 28–37 55 33.3 (26.2–41.1)
 38–47 33 20.0 (14.2–26.9)
 48–57 15 9.1 (5.2–14.6)
Level of education
 Primary 9 5.5 (2.5–10.1)
 Secondary 46 27.9 (21.2–35.4)
 Tertiary 80 48.5 (40.6–56.4)
 Post-graduate 12 7.3 (3.8–12.4)
 Qur’anic/Islamiyya only 17 10.3 (6.1–16.0)
 None 1 0.6 (0.01–3.3)
Occupation
 Civil servant 49 29.7 (22.8–37.3)
 Self-employed 40 24.2 (17.9–31.5)
 Non-governmental employee 3 1.8 (0.4–5.2)
 Retired 1 0.6 (0.02–3.3)
 Student 38 23.0 (16.8–30.2)
 Homemaker 30 18.2 (12.6–24.9)
 Others 4 2.4 (0.7–6.1)
Marital status
 Single 59 35.8 (28.5–43.6)
 Married 99 60.0 (52.1–67.5)
 Divorced 3 1.8 (0.4–5.2)
 Widowed 4 2.4 (0.7–6.1)
Open in a new tab

Univariate analysis showing the frequency and percentages with 95% CI.

CI: Confidence interval, IQR: Interquartile range

Out of the 165 HBsAg-positive samples collected, 138 (83.6%) were HBV-DNA positive [Figure 1]. Electrophoretogram of samples from HBsAg-positive HBV-DNA-positive study participants show bands representing identified genotypes. Bands from Mix ‘A’ of the primers set-up were shown at the upper part of the gel, while bands from Mix ‘B’ were shown at the lower part of the gel. Genotypes A, B and C with band sizes of 68 bp, 281 bp and 122 bp, respectively, were identified in Mix ‘A’, while genotypes D and E with band sizes of 119 bp and 167 bp, respectively, were identified in Mix ‘B’. Molecular marker (M) of 100 base pairs plus (100 bp+) served as the marker for identifying the genotypes of the HBV. Sample #155 showed mixed genotype infection with genotypes B and E; sample #156 had mixed genotypes B, C and E; sample #159 showed mixed genotypes of B and D; while sample #163 showed mixed genotypes of A and E [Figure 2]. Out of the 138 HBsAg-positive HBV-DNA-positive samples, 114 (82.6%) had mixed HBV genotypes infection, while the remaining 24 (17.4%) had single-genotype infection [Figure 3]. With respect to the pattern of infections, genotypes E + B mixed-infection had the highest frequency of 82 (59.5%), while the least frequent were genotype B mono-infection and genotypes D+B+A mixed-infection each with 1 (0.7%) [Figure 4]. Stratifying the HBV genotypes by age group and sex, there was no significant association between either the age group and HBV genotypes (P = 0.8024) or sex and the HBV genotypes (P = 0.7501) [Table 3]. For the HBV-DNA-positive samples analysed for genotyping, genotype E was most prevalent with 134 (97.1%), while genotype D had 1 (0.7%) [Figure 5].

Figure 1:

Figure 1:

Open in a new tab

Proportion of HBV surface antigen-positive participants with HBV-DNA positivity and negativity by primer-specific nested polymerase chain reaction. A pie chart showing a greater proportion of the HBV-DNA-positive samples (138/165). HBV: Hepatitis B virus

Figure 2:

Figure 2:

Open in a new tab

Agarose gel electrophoretogram of HBV surface antigen-positive HBV DNA+ samples. Mix A and B identifying HBV genotypes A (68bp), B (281bp), C (122bp), D (119bp) and E (167bp). M: 100bp+ molecular marker; (−): Negative control; Representative samples 155–170 samples. HBV: Hepatitis B virus

Figure 3:

Figure 3:

Open in a new tab

Pattern of HBV infection in Zaria. Pie chart showing proportions of mono- and mixed-infections with HBV in HBV-DNA-positive patients in Zaria, Nigeria. HBV: Hepatitis B virus

Figure 4:

Figure 4:

Open in a new tab

Hepatitis B virus genotypes distribution in HBV-DNA-positive samples in Zaria. A bar chart showing HBV genotypes in mono- and mixed-infection patterns prevalent in Zaria, Nigeria. HBV: Hepatitis B virus

Table 3:

Sex and age stratification for the distribution of hepatitis B virus genotypes in Zaria, Nigeria

Variable HBV/A (%) HBV/B (%) HBV/C (%) HBV/D (%) HBV/E (%) Statistics (Yatesχ2, df, P)
Age range
 18–27 17 (12.3) 42 (30.4) 11 (8.0) 0 (0.0) 50 (36.2) 7.775, 12, 0.8024
 28–37 9 (6.5) 39 (28.3) 8 (5.8) 0 (0.0) 45 (32.6)
 38–47 7 (5.1) 23 (16.7) 4 (2.9) 1 (0.7) 28 (20.3)
 48–57 1 (0.7) 10 (7.2) 1 (0.7) 0 (0.0) 11 (8.0)
 Total 34 (24.6) 114 (82.6) 24 (17.4) 1 (0.7) 134 (97.1)
Sex
 Male 19 (13.8) 76 (55.1) 15 (10.9) 1 (0.7) 85 (61.6) 1.922, 4, 0.7501
 Female 15 (10.9) 38 (27.5) 9 (6.5) 0 (0.0) 49 (35.5)
 Total 34 (24.6) 114 (82.6) 24 (17.4) 1 (0.7) 134 (97.1)
Open in a new tab

HBV: Hepatitis B virus

Figure 5:

Figure 5:

Open in a new tab

HBV single genotypes distribution in HBV-DNA-positive samples in Zaria. A column chart showing the prevalence of HBV genotypes in Zaria, Nigeria. HBV: Hepatitis B virus

Discussion

In Nigeria, most of the studies conducted on HBV were restricted to the prevalence of the virus in different population subgroups such as blood donors,[21] pregnant women and children,[22,23] and some focused on a meta-analysis which pooled the different subgroups to arrive at some figures.[24] A recent national survey focusing on the prevalence and risk factors associated with HBV infection[8] is also available, the final findings of which informed the sample size used for this study. Hepatitis B infection is a vaccine-preventable disease, the vaccine which was included in the Nigerian national immunisation schedule in 1995 only to be available in 2004.[22,25,26] The participants in this studyhad a median age of 31.0 (25.5–39.0) years and a minimum age of 18 years did not have the privilege of getting the shots of the hepatitis B vaccines at birth, as they were all born before the inclusion of the vaccine in the national immunisation schedule. The study showed there were more male participants with HBV as compared to the female participants. This agreed with other previous studies.[16,17] The underlying higher prevalence of HBV among men in Africa could explain the male predominant cohort.

Our study was able to detect and genotype the infecting HBV in 83.6% (138/165) of the collected samples. This was consistent with the findings in Egypt[27] using innogenetics line probe assay (INNO-LiPA) which is based on the reversed hybridisation principle; in the United Arab Emirates using the nucleic acid testing (NAT);[28] in Cote d’Ivoire using nested PCR;[17] in India,[29] using the NAT and in Wasit province of Iraq[16] using nested PCR where they were able detect and genotype 71.4%, 95%, 68.7%, 69.7% and 60.5%, respectively. Similarly, much earlier, using mini-pool and single-sample PCR assays, another study[30] detected HBV-DNA in 69% of HBsAg-positive samples. The different methodologies applied maintained the variability in HBV-DNA isolation in relation to HBsAg positivity, in that not all HBsAg-positive samples yielded positive results for HBV-DNA detection, irrespective of the method of detection. Being a non-encapsulated virus, HBV-DNA tends to rapidly degrade, whereas in the absence of or with inadequate anti-HBs, viral surface antigen may remain in circulation for a prolonged periods of time.[31] This could depend on the stage of infection such as in patients who are chronic carriers with inactive infection. It could also be explained by intermittent viraemia or an extremely low and undetectable levels of HBV-DNA either due to prior treatment or natural clearance.[32]

Mixed genotype infection was shown to dominate over single genotype infection with 82.6% (114/165) as against the latter with 17.4% (24/165). This agrees with the findings in Iraq,[33] where they documented all 4 HBV-DNA-positive samples to have mixed genotype infections with 75% (3/4) harbouring 4 different genotypes and 25% (1/4) harbouring 3. It is also in agreement with the findings in Iraq,[16] where they identified mixed genotype infection in all the samples, recording not a single sample with single genotype infection. Our findings of mixed genotype infection constituting the better portion, however, disagrees with that of a finding in Taiwan,[34] where mono-infection with genotype B was identified to predominate. It also disagrees with a study in Paris[35] where in comparing direct sequencing with INNO-LiPA HBV genotyping assay, 85.3% was found to harbour a single genotype. The mixed-infection recorded in our study could be as a result of possible recombination between genotypes as noted in earlier findings.[36–38] It could also be as a result of migrations and long-term travels for overseas studies and peacekeeping missions by military personnel.

In all, the identification of the five HBV genotypes in this study, namely, A, B, C, D and E corroborates the assertions[39,40] that all of them are more frequently detected in Africa. Regardless of occurrence in the form of mixed or mono-infection, this study identified genotype E to be with the highest prevalence. This was followed by genotype B, then genotypes A, then C and genotype D with the least prevalence. However, where occurring as mono-infection, HBV/E still predominates with HBV/A being the second most prevalent with HBV/B being the least. Mixed-infection of HBV/E+B has the highest occurrence in all, which was followed by HBV/E+B+C+A, HBV/E+ B + A and HBV/E+B+C with the least mixed-infection being HBV/D+B+A. Available literature have proclaimed genotype E to be the predominant genotype in Nigeria[11,41,42] and the Sub-Saharan Africa in general.[43–45] This has confirmed the inclusion of Nigeria in the crescent of HBV genotype E in Sub-Saharan Africa from Senegal in the West to the Central African Republic in the East and Namibia in the South.[39,46,47] It is a common belief that genotype E is almost exclusively found only in Africa, with few exceptions on other continents with links to Africans.[48] This study is in agreement with the previous studies that showed E to be the most prevalent genotype in West Africa with genotype A being the second most prevalent, both having originated from the region.[48] Although there was no specific mention of the prevalence rate of HBV/B in Nigeria or any West African country, it is believed that it is detected in Africa.[40] Genotype B identified in this study appears to be favoured by prior infection of another genotype where it counts as a super-infection or has high recombination tendencies, considering that it is the second most prevalent genotype. Genotype D that was the least identified genotype is not unexpected as the previous studies have identified genotype D6 subtype ayw2 in Nigeria.[49]

Conclusion

HBV infection in Zaria is mostly characterised by mixed genotype infections. Irrespective of occurrence as mixed- or mono-infection, five genotypes of HBV are prevalent in Zaria, Nigeria, with HBV/E (97.1%) predominating, followed by HBV/B (82.6%), HBV/A (24.6%), HBV/C (17.4%) and HBV/D (0.7%) having the least occurrence. Most of the mixed-infection are a combination of genotype E, the predominant genotype, then other genotypes predominantly genotype B that appear to co- or super-infect.

Limitation

The multiplex nested PCR method applied for genotyping HBV is capable of identifying only six genotypes; A-F, limiting this study to identifying only those. Genotypes G-J might have been missed by this method.

Financial support and sponsorship

Research reported in this publication was supported by the Fogarty International Center (FIC); Office of the Director (OD/NIH); National Institute of Neurological Disorders and Stroke (NINDS/NIH); and the National Institute of Nursing Research (NINR/NIH) of the National Institutes of Health under Award Number D43 TW010130. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health.

Footnotes

Conflicts of interest

There are no conficts of interest.

References

  • 1.Caley M, Fowler T, Greatrex S, Wood A. Differences in hepatitis B infection rate between ethnic groups in antenatal women in Birmingham, United Kingdom, May 2004 to December 2008.Euro Surveill 2012;17 pii:20228. [PubMed] [Google Scholar]
  • 2.World Health Organization; Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. France: World Health Organization; 2015. Available from: http://www.who.int/hiv/topics/hepatitis/en/. [Last accessed on 2018 Sep 30]. [PubMed] [Google Scholar]
  • 3.Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fasola FA, Kotila TR, Akinyemi JO. Trends in transfusion-transmitted viral infections from 2001 to 2006 in Ibadan, Nigeria. Intervirology 2008;51:427–31. [DOI] [PubMed] [Google Scholar]
  • 5.Forbi JC, Onyemauwa N, Gyar SD, Oyeleye AO, Entonu P, Agwale SM, et al. High prevalence of hepatitis B virus among female sex workers in Nigeria. Rev Inst Med Trop Sao Paulo 2008;50:219–21. [DOI] [PubMed] [Google Scholar]
  • 6.Bello RH, Obot E, Olabode HO. Sero-prevalence and risk factors associated with hepatitis B surface antigen (HBsAg) amongst patients in Biu, Borno state, Nigeria. J Public Health Epidemiol 2011;3:448–53. [Google Scholar]
  • 7.Ndako JA, Onwuliri EA, Adelani-Akande T, Olaolu DT, Dahunsi SO, Udo UD. Screening for hepatitis B surface antigen (HBsAg) among health care workers (HCW) in an urban community South-South Nigeria. Int J Biol Pharm Allied Sci 2014;3:415–25. [Google Scholar]
  • 8.Olayinka AT, Oyemakinde A, Balogun MS, Ajudua A, Nguku P, Aderinola M, et al. Seroprevalence of hepatitis B infection in Nigeria: A national survey. Am J Trop Med Hyg 2016;95:902–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009;83:10538–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mahmood M, Anwar MA, Khanum A, Zaman N, Raza A. Distribution and clinical significance of hepatitis B virus genotypes in Pakistan . BMC Gastroenterol 2016;16:104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Odemuyiwa SO, Mulders MN, Oyedele OI, Ola SO, Odaibo GN, Olaleye DO, et al. Phylogenetic analysis of new hepatitis B virus isolates from Nigeria supports endemicity of genotype E in West Africa. J Med Virol 2001;65:463–9. [PubMed] [Google Scholar]
  • 12.Schaefer S Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 2007;13:14–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011;26Suppl 1:123–30. [DOI] [PubMed] [Google Scholar]
  • 14.Boglione L, Cusato J, Cariti G, Di Perri G, D’Avolio A. The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon. J Infect 2014;69:81–7. [DOI] [PubMed] [Google Scholar]
  • 15.Croagh CM, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol 2015;7:289–303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Al-Suraifi AS, Al-Rubaie AD, Al-Mayahie SM, Al-Abedy NMM. Unusual HBV mixed genotype infections among hepatitis type b Iraqi patients in Wasit province/Iraq. Int J Biomed Eng Clin Sci 2016;2:1–7. [Google Scholar]
  • 17.Doumbia M, Kouassi MA, Kakou NS, Sevede D. Molecular characterization of hepatitis B virus isolated from two groups of patients at risk in Côte d’Ivoire. J Microbiol Res Rev 2013;1:61–6. [Google Scholar]
  • 18.Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J Clin Microbiol 2001;39:362–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lindh M, Gonzalez JE, Norkrans G, Horal P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J Virol Methods 1998;72:163–74. [DOI] [PubMed] [Google Scholar]
  • 20.Ahmad AE, Bakari AG, Musa BOP, Mustapha SK, Nasir IA, Tahir MI, et al. HBV genotyping by multiplex nested PCR. Protocols.io. Deposited on: 10.17504/protocols.io.p79drr6. [Last published on 2018 May 19]. [DOI] [Google Scholar]
  • 21.Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH, et al. Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005;100:13–6. [DOI] [PubMed] [Google Scholar]
  • 22.Sadoh AE, Ofili A. Hepatitis B infection among Nigerian children admitted to a children’s emergency room. Afr Health Sci 2014;14:377–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ikobah J, Okpara H, Elemi I, Ogarepe Y, Udoh E, Ekanem E, et al. The prevalence of hepatitis B virus infection in Nigerian children prior to vaccine introduction into the National Programme on Immunization Schedule. Pan Afr Med J 2016;23:128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Musa BM, Bussell S, Borodo MM, Samaila AA, Femi OL. Prevalence of hepatitis B virus infection in Nigeria, 2000–2013: A systematic review and meta-analysis. Niger J Clin Pract 2015;18:163–72. [DOI] [PubMed] [Google Scholar]
  • 25.Federal Ministry of Health. National Immunization Policy and Standard of Practice. Lagos, Nigeria: Federal Ministry of Health; 1995. [Google Scholar]
  • 26.World health organization. The weekly epidemiological record: hepatitis B vaccines. Geneva: 2009;84:405–20. [Google Scholar]
  • 27.Khaled IA, Mahmoud OM, Saleh AF, Baioumi EA. Prevalence of HBV genotypes in Egypt among hepatitis patients. J Am Sci 2010;6:185–90. [Google Scholar]
  • 28.Al Shaer L, AbdulRahman M, John TJ, AlHashimi A. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: Impact of individual-donation nucleic acid testing, 2004 through 2009. Transfusion 2012;52:2300–9. [DOI] [PubMed] [Google Scholar]
  • 29.Pandey P, Tiwari AK, Dara RC, Aggarwal G, Rawat G, Raina V, et al. A comprehensive serological and supplemental evaluation of hepatitis B “seroyield” blood donors: A cross-sectional study from a tertiary healthcare center in India. Asian J Transfus Sci 2015;9:189–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002;42:869–75. [DOI] [PubMed] [Google Scholar]
  • 31.Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999;107:186–95. [DOI] [PubMed] [Google Scholar]
  • 32.Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP, et al. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: Implications for future HBV screening policy. Transfusion 2004;44:1332–9. [DOI] [PubMed] [Google Scholar]
  • 33.Rashid PM, Salih GF. Identification and genotyping of hepatitis B virus by PCR assay using genotype specific primers. Eur Sci J 2014;10:424–33. [Google Scholar]
  • 34.Liu CJ, Kao JH, Chen DS. Mixed hepatitis B virus genotype infections: The more, the worse? Hepatology 2006;1:770 [DOI: 10.1002/hep.21342]. [DOI] [PubMed] [Google Scholar]
  • 35.Mercier M, Laperche S, Girault A, Sureau C, Servant-Delmas A. Overestimation of incidence of hepatitis B virus mixed-genotype infections by use of the new line probe INNO-liPA genotyping assay. J Clin Microbiol 2011;49:1154–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Chen JD, Liu CJ, Lee PH, Chen PJ, Lai MY, Kao JH, et al. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004;2:64–71. [DOI] [PubMed] [Google Scholar]
  • 37.Olinger CM, Venard V, Njayou M, Oyefolu AO, Maïga I, Kemp AJ, et al. Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: New subtypes, mixed infections and recombinations. J Gen Virol 2006;87:1163–73. [DOI] [PubMed] [Google Scholar]
  • 38.Locarnini S, Littlejohn M, Aziz MN, Yuen L. Possible origins and evolution of the hepatitis B virus (HBV). Semin Cancer Biol 2013;23:561–75. [DOI] [PubMed] [Google Scholar]
  • 39.Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 2007;37:S9–19. [DOI] [PubMed] [Google Scholar]
  • 40.Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol 2015;21:11941–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Forbi JC, Vaughan G, Purdy MA, Campo DS, Xia GL, Ganova-Raeva LM, et al. Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria. PLoS One 2010;5:e11615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Faleye TO, Adewumi MO, Ifeorah IM, Omoruyi EC, Bakarey SA, Akere A, et al. Detection of hepatitis B virus isolates with mutations associated with immune escape mutants among pregnant women in Ibadan, Southwestern Nigeria. Springerplus 2015;4:43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Forbi JC, Ben-Ayed Y, Xia GL, Vaughan G, Drobeniuc J, Switzer WM, et al. Disparate distribution of hepatitis B virus genotypes in four sub-Saharan African countries. J Clin Virol 2013;58:59–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Andriamandimby SF, Lo Presti A, Lai A, Olive MM, Angeletti S, De Florio L, et al. Genetic diversity of hepatitis B virus (HBV) in Madagascar. J Med Virol 2016;88:2138–44. [DOI] [PubMed] [Google Scholar]
  • 45.Candotti D, Diarra B, Bisseye C, Tao I, Pham Quang K, Sanou M, et al. Molecular characterization of hepatitis B virus in blood donors from Burkina Faso: Prevalence of quasi-subgenotype A3, genotype E, and mixed infections. J Med Virol 2016;88:2145–56. [DOI] [PubMed] [Google Scholar]
  • 46.Vray M, Debonne JM, Sire JM, Tran N, Chevalier B, Plantier JC, et al. Molecular epidemiology of hepatitis B virus in Dakar, Sénégal. J Med Virol 2006;78:329–34. [DOI] [PubMed] [Google Scholar]
  • 47.Bekondi C, Olinger CM, Boua N, Talarmin A, Muller CP, Le Faou A, et al. Central African republic is part of the West-African hepatitis B virus genotype E crescent. J Clin Virol 2007;40:31–7. [DOI] [PubMed] [Google Scholar]
  • 48.Andernach IE, Nolte C, Pape JW, Muller CP. Slave trade and hepatitis B virus genotypes and subgenotypes in Haiti and Africa. Emerg Infect Dis 2009;15:1222–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Kramvis A Genotypes and genetic variability of hepatitis B virus. Intervirology 2014;57:141–50. [DOI] [PubMed] [Google Scholar]

RESOURCES